B
Bonnie Yates
Researcher at National Institutes of Health
Publications - 57
Citations - 2271
Bonnie Yates is an academic researcher from National Institutes of Health. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 13, co-authored 39 publications receiving 1270 citations.
Papers
More filters
Journal ArticleDOI
CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy.
Terry J. Fry,Nirali N. Shah,Rimas J. Orentas,Maryalice Stetler-Stevenson,Constance M. Yuan,Sneha Ramakrishna,Pamela L. Wolters,Staci Martin,Cindy Delbrook,Bonnie Yates,Haneen Shalabi,Thomas J. Fountaine,Jack F. Shern,Robbie G. Majzner,David F. Stroncek,Marianna Sabatino,Yang Feng,Dimiter S. Dimitrov,Ling Zhang,Sang M. Nguyen,Haiying Qin,Boro Dropulic,Daniel W. Lee,Crystal L. Mackall +23 more
TL;DR: These results are the first to establish the clinical activity of a CD22-CAR in B-all, including leukemia resistant to anti-CD19 immunotherapy, demonstrating potency against B-ALL comparable to that of CD19-CAR at biologically active doses.
Journal ArticleDOI
CD4/CD8 T-Cell Selection Affects Chimeric Antigen Receptor (CAR) T-Cell Potency and Toxicity: Updated Results From a Phase I Anti-CD22 CAR T-Cell Trial
Nirali N. Shah,Steven L. Highfill,Haneen Shalabi,Bonnie Yates,Jianjian Jin,Pamela L. Wolters,Amanda K. Ombrello,Seth M. Steinberg,Staci Martin,Cindy Delbrook,Leah Hoffman,Lauren Little,Anusha Ponduri,Haiying Qin,Haris Qureshi,Alina Dulau-Florea,Dalia Salem,Hao-Wei Wang,Constance M. Yuan,Maryalice Stetler-Stevenson,Sandhya R. Panch,Minh Tran,Crystal L. Mackall,Crystal L. Mackall,David F. Stroncek,Terry J. Fry,Terry J. Fry +26 more
TL;DR: The remission induction rate supports further development of CD22 CAR T cells as a therapeutic option in patients resistant to CD19-targeted immunotherapy, and novel information on the impact of manufacturing changes on clinical outcomes is provided.
Journal ArticleDOI
Long-Term Follow-Up of CD19-CAR T-Cell Therapy in Children and Young Adults With B-ALL.
Nirali N. Shah,Daniel W. Lee,Bonnie Yates,Constance M. Yuan,Haneen Shalabi,Staci Martin,Pamela L. Wolters,Seth M. Steinberg,Eva H. Baker,Cindy Delbrook,Maryalice Stetler-Stevenson,Terry J. Fry,David F. Stroncek,Crystal L. Mackall +13 more
TL;DR: PURPOSECD19 chimeric antigen receptor (CD19-CAR) T cells induce high response rates in children and young adults (CAYAs) with B-cell acute lymphoblastic leukemia (B-ALL) but relapse rates are high as discussed by the authors.
Journal ArticleDOI
Sequential loss of tumor surface antigens following chimeric antigen receptor T-cell therapies in diffuse large B-cell lymphoma
Haneen Shalabi,Ira Lignugaris Kraft,Hao-Wei Wang,Constance M. Yuan,Bonnie Yates,Cindy Delbrook,Julie D. Zimbelman,Roger Giller,Maryalice Stetler-Stevenson,Elaine S. Jaffe,Daniel W. Lee,Jack F. Shern,Terry J. Fry,Nirali N. Shah +13 more
TL;DR: This case provides a proof of concept of antigen loss as a mechanism for relapse following immunotherapy in lymphomas, and highlights the need for repeat biopsy and flow cytometric analysis in guiding sequential immunotherapeutic interventions.
Journal ArticleDOI
Long-Term Outcomes Following CD19 CAR T Cell Therapy for B-ALL Are Superior in Patients Receiving a Fludarabine/Cyclophosphamide Preparative Regimen and Post-CAR Hematopoietic Stem Cell Transplantation
Daniel W. Lee,Maryalice Stetler-Stevenson,Constance M. Yuan,Nirali N. Shah,Cindy Delbrook,Bonnie Yates,Hua Zhang,Ling Zhang,James N. Kochenderfer,Steven A. Rosenberg,Terry J. Fry,David F. Stroncek,Crystal L. Mackall +12 more
TL;DR: Outcomes from a completed clinical trial of 53 children and young adults with relapsed/refractory ALL and 6 subjects with CNS ALL were rendered into CNS1 status with resolution of leptomeningeal enhancement, where appropriate, and CAR cells in CSF.